ReviewWorld journal of gastroenterology2010
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Review in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.Deutsches Arzteblatt international · 2014Trial
- Outcomes of palliative porto-mesenteric venous stenting in unresectable pancreatic malignancies.The oncologist · 2025Article
- The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAPActa pharmaceutica Sinica. B · 2022Article
- Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells.Cell & bioscience · 2019Article
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Parasitic Mistletoes of the Genera Scurrula and Viscum: From Bench to Bedside.Molecules (Basel, Switzerland) · 2016Review
- Clinical Translation of Nanomedicine.Chemical reviews · 2015Review
- Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma.PloS one · 2014Article
- Triple approach strategy for patients with locally advanced pancreatic carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013Observational
- Article
- Article
- Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.PloS one · 2013Article
- Costs and trends in pancreatic cancer treatment.Cancer · 2012Article
- Article
- Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.International journal of nanomedicine · 2012Review
- Polycomb and the emerging epigenetics of pancreatic cancer.Journal of gastrointestinal cancer · 2011Review
- CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.Cancer research · 2011Article
- Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.British journal of cancer · 2011Article
- The burning question: why is smoking a risk factor for pancreatic cancer?Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]Review
- The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis.PancreasReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of advances made in the management of the other more common cancers of the gastrointestinal tract, significant progress in the treatment of pancreatic cancer remains elusive. Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease. Until recently, the only treatment with an impact on survival was surgery. In the palliative setting, gemcitabine (Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil. Since then, clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically "targeted" agents. However, promising trial results in small phase II trials have not translated into survival improvements in larger phase III randomized trials in the advanced disease setting. Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine (United Kingdom National Cancer Research GEMCAP trial) or erlotinib (National Cancer Institute of Canada Clinical Trials Group PA.3 trial). This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer, summarizing the results of several recent clinical trials and discuss their implications for clinical practice. We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.